Immunogenicity and effect of 13-valent pneumococcal polysaccharide conjugate vaccine in adults

Streptococcus pneumoniae is one of important pathogens causing severe illnesses and deaths in adults, especially in the elderly. 13-Valent pneumococcal polysaccharide conjugate vaccine (PCV13) has been approved in many countries or regions for the prevention of invasive and non-invasive pneumococcal disease in adults, but not be approved in the mainland of China. This study reviews researches on immunogenicity and effect of PCV13 in adults to provide evidence for optimizing PCV13 immunization strategy in the mainland of China.